Previous 10 | Next 10 |
Summary ImmunityBio operates an effective development program for infectious disease, and more interestingly, oncology therapies. Its duly accepted BLA will be in the spotlight as its PDUFA date rolls around. The company's attraction as an investment is uncertain and should on...
Shares of ImmunityBio have lost nearly 90% of their value since merger with NantKwest last year. Ties to biotech billionaire Patrick Soon-Shiong are a net positive, especially in light of his success selling prior company Abraxis to Pfizer for $2.9 billion. Data for lead indicatio...
ImmunityBio ( NASDAQ: IBRX ) on Thursday said the U.S. FDA had accepted for review the company's biologics license application (BLA) for its agonist N-803 for the treatment of bladder cancer carcinoma in situ. The exact indication for N-803 is for the treatment of pati...
This acceptance represents the first regulatory filing for N-803, an IL-15 superagonist, which was granted Breakthrough Therapy and Fast Track designations in combination with Bacillus Calmette-Guérin (BCG) from the U.S. Food and Drug Administration (FDA) for this indication ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Big pharma stocks gained impressively during the pandemic years for obvious reasons. However, with the pandemic in the rear-view mirror, the best pharmaceutical stocks continue to perform remarkably well. This is a welcome ...
We conclude our roundtable series with Biotech and Healthcare coverage. Seven of our Marketplace contributors give their analysis and share one top idea. Look for more roundtables and analysis this summer from our community of 180+ Marketpalce services. ~ By Tim Murphy, Ma...
Gainers: Kezar Life Sciences (KZR) +99%. Iris Energy (IREN) +5%. Immunity (IBRX) +5%. Cognyte Software (CGNT) +4%. Braze (BRZE) +4%. Losers: Polestar Automotive Holding (PSNYW) -5%. TripAdvisor (TRIP) -4%. Robinhood Market (HOOD) -4%. ADMA Biologics (ADMA) -3%. Concentrix Corporatio...
Data presented by ImmunityBio (NASDAQ:IBRX) at the American Society for Clinical Oncology Annual Conference showed positive results from two trials in bladder cancer carcinoma and advanced pancreatic cancer. In a pivotal trial, 71% of BCG-unresponsive patients treated with Bacillus Calmette-G...
Data from trials underscore ImmunityBio’s vision of activating NK cells and T cells to advance care in difficult-to-treat cancers Bladder Cancer: 71% of BCG-unresponsive NMIBC patients who had failed on previous therapies showed a complete response with a median duratio...
ImmunityBio has finally submitted the Anktiva (N-803) and BCG combination BLA in NMIBC ahead of the final clinical results presentation at ASCO. The company is still moving forward with multiple cancer and infectious disease programs with Anktiva. An FDA approval would improve the out...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...